Jane M. Love, Ph.D. is a partner and Chair of the Life Sciences and the Intellectual Property Litigation practices at Gibson Dunn & Crutcher LLP.  Dr. Love is resident in the New York office.

Dr. Love is a first-chair litigator who handles high value patent litigation for pharma and biotech companies including global litigation coordination.  She has extensive experience in Hatch-Waxman and BPCIA litigation.  As a registered patent attorney, Jane is often lead counsel in concurrent Patent Office proceedings.  Jane routinely offers strategic patent prosecution advice and patent diligence advice in connection with high value transactions.

Dr. Love has litigated patent issues in many jurisdictions around the country including Delaware, New Jersey, California, Massachusetts, and others.  Her cases have spanned a wide variety of technologies but of late focus on biologics, therapeutic nucleic acids, and small molecules.  She has advised clients on antibodies, immunotherapies, genetics, vaccines, protein therapies, blood factors, medical devices, diagnostics, gene therapies, RNA therapies, bioinformatics and nanotechnology.  She is a patent attorney registered to practice before the U.S. Patent and Trademark Office and has prosecuted hundreds of patent applications.

Dr. Love is Chambers-rated for Intellectual Property, and has twice been named “Life Sciences MVP” by Law360 (2017 and 2019). The National Law Journal named her a 2020 Health Care/Life Science Trailblazer in recognition for her work representing Novartis AG’s multiple sclerosis drug Gilenya in cases impacting patent owners and challengers across the pharmaceutical and biotech industries. She and her team won “Hatch-Waxman Impact Case of the Year” in 2019 for a case related to patent term extensions and terminal disclaimers which Dr. Love won in Delaware District court and argued before the Federal Circuit. She is consistently named an “IP Star” by Managing IP and is recognized as one of the “world’s leading patent professionals” by IAM Patent. Dr. Love was recognized as “Best in Patent” at the 2018 Euromoney Legal Media Group Women in Business Law Awards. In addition, she has been named in 2017 and 2020 in Legal Media Group’s Expert Guides Guide to the World’s Leading Women in Business Law for Patents.  Dr. Love has been named a “Life Sciences Star” for Intellectual Property by LMG Life Sciences.  She was named one of the “Top 250 Women in IP” by Managing IP in its seven most recent lists and was named one of the IP attorneys in the “Top 50 Under 45” list by IP Law & Business in 2008.

Before joining Gibson Dunn, Dr. Love was the Co-Vice Chair of the Intellectual Property Department of Wilmer Hale and associated with that firm in New York since 2001.  For seven years before that, Dr. Love practiced in an IP boutique law firm in New York.

Dr. Love received her Juris Doctor from Fordham University School of Law.  Before practicing law, Dr. Love was a Ph.D. graduate student at the University of Pennsylvania and Thomas Jefferson Medical School in Philadelphia and was a Post-Doctoral Research Fellow at Cornell University Weill Medical College in New York City in molecular biology, pharmacology and cell and developmental biology.

Dr. Love served as a Captain in the U.S. Army Reserve Medical Service Corp from 1991 to 1997.

Representative cases:

• Confidential case: Lead counsel in preparation for litigation under BPCIA for biosimilar manufacturer.
• Novartis Pharmaceuticals Corp.: Lead counsel in ANDA litigation against multiple generic defendants enforcing patents covering Gilenya®, the first oral treatment for multiple sclerosis.
• Novartis Pharmaceuticals Corp.: Lead counsel in inter partes review (IPR) defending patent covering Gilenya^® against three petitioners before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office.
• Merck Sharp & Dohme: Lead counsel in a Delaware district court defense and related IPR against a formulation patent asserted by Mayne Pharmaceuticals based on sales of Merck’s Noxafil anti-fungal product.
• Novartis Pharmaceuticals Corp.: Lead counsel in ANDA litigation against more than 20 generic defendants enforcing several patents covering Reclast®and Zometa®, treatments for osteoporosis and cancer.
• Novartis Pharmaceuticals Corp.: Co-lead counsel in ANDA litigation against multiple generic defendants enforcing patents covering Exjade®, a medicine for treatment of iron overload resulting from blood transfusions.
• Confidential client: Advice related to Biologics Price Competition and Innovation Act of 2009 (BPCIA) and defense against biosimilar challenges.
• AbbVie, Inc.: Co-lead counsel in patent litigation asserting patents directed to human antibodies directed against the cytokine IL-12 (Stelara®) and methods to treat autoimmune diseases.
• Confidential client: International arbitration related to patents covering gene sequencing devices and methods.
• Alnylam, Inc.: Lead counsel in a patent interference before the Board of Patent Appeals and Interferences at the U.S. Patent and Trademark Office related to small interfering RNAs, siRNAs, used for the treatment of cancer.
• Japanese Foundation for Cancer Research: Co-lead counsel in patent interference before the Board of Patent Appeal and Interferences at the U.S. Patent and Trademark Office related to nucleic acids encoding interferon-beta, one of the first human proteins cloned.
• Cephalon, Inc.: ANDA litigation enforcing patents covering Provigil®, a drug used to aid in wakefulness.
• Hologic, Inc.: Lead counsel in a patent interference before the Board of Patent Appeals and Interferences at the U.S. Patent and Trademark Office related to breast biopsy devices.

Publications:

• Co-Author, “TC Heartland And Hatch-Waxman: Square Peg In Round Hole,” Law360, January 30, 2018.